📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Dynacure

1.1 - Company Overview

Dynacure Logo

Dynacure

Headquarter: France
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage drug development focused on rare and orphan diseases, building a pipeline of novel antisense therapies. Offerings include DYN101, an investigational antisense medicine; danvatirsen (STAT3), in Phase 2 for HNSCC and Phase 1 for AML/MDS; FTX-001 (MALAT1), ready for clinical trials; and PEMDA-HN, a study of danvatirsen with pembrolizumab for recurrent/metastatic HNSCC.

Products and services

  • Danvatirsen: A STAT3-targeted antisense oligonucleotide, in Phase 2 for head and neck squamous cell carcinoma and Phase 1 for acute myeloid leukemia and myelodysplastic syndrome
  • PEMDA-HN: An open-label study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma patients
  • FTX-001: A MALAT1-targeted antisense oligonucleotide, ready for clinical trials to address undruggable cancer targets within oncology therapeutic development

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Dynacure

Brabant Pharma Logo

Brabant Pharma

HQ: Vietnam Website
  • Description: Provider of a late-stage oral treatment, Brabafen, under development for children with Dravet Syndrome (severe myoclonic epilepsy of infancy), a rare childhood epilepsy associated with catastrophic seizures resulting in mental and cognitive impairment.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Brabant Pharma company profile →
Zymenex Logo

Zymenex

HQ: Denmark Website
  • Description: Provider of novel enzyme replacement therapies for life-threatening, rare genetic diseases; a Scandinavian biopharmaceutical company developing and commercializing human recombinant enzymes for therapeutic use.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Zymenex company profile →
AveXis Logo

AveXis

HQ: United States Website
  • Description: Provider of gene therapies specializing in the development and commercialization for patients and families affected by rare and life-threatening neurological genetic diseases; doing business as Novartis Gene Therapies, Inc. following Novartis’s 2018 acquisition and 2020 renaming.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full AveXis company profile →
Soin Therapeutics Logo

Soin Therapeutics

HQ: United States Website
  • Description: Provider of pharmaceutical drug development focused on new medications for rare, orphan diseases, including a novel formulation of low-dose naltrexone to treat CRPS.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Soin Therapeutics company profile →
Aeovian Pharmaceuticals Logo

Aeovian Pharmaceuticals

HQ: United States Website
  • Description: Provider of therapeutics for rare and age-related diseases, focused on discovering, developing, and commercializing treatments.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aeovian Pharmaceuticals company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Dynacure

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Dynacure

2.2 - Growth funds investing in similar companies to Dynacure

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Dynacure

4.2 - Public trading comparable groups for Dynacure

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Dynacure

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Dynacure

What does Dynacure do?

Dynacure is a provider of clinical-stage drug development focused on rare and orphan diseases, building a pipeline of novel antisense therapies. Offerings include DYN101, an investigational antisense medicine; danvatirsen (STAT3), in Phase 2 for HNSCC and Phase 1 for AML/MDS; FTX-001 (MALAT1), ready for clinical trials; and PEMDA-HN, a study of danvatirsen with pembrolizumab for recurrent/metastatic HNSCC.

Who are Dynacure's competitors?

Dynacure's competitors and similar companies include Brabant Pharma, Zymenex, AveXis, Soin Therapeutics, and Aeovian Pharmaceuticals.

Where is Dynacure headquartered?

Dynacure is headquartered in France.

How many employees does Dynacure have?

Dynacure has 1,000 employees 🔒.

When was Dynacure founded?

Dynacure was founded in 2010 🔒.

What sector and industry vertical is Dynacure in?

Dynacure is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Dynacure

Who are the top strategic acquirers in Dynacure's sector and industry

Top strategic M&A buyers and acquirers in Dynacure's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Dynacure?

Top strategic M&A buyers groups and sectors for Dynacure include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Dynacure's sector and industry vertical

Which are the top PE firms investing in Dynacure's sector and industry vertical?

Top PE firms investing in Dynacure's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Dynacure's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Dynacure's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Dynacure's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Dynacure include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Dynacure's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Dynacure?

The key public trading comparables and valuation benchmarks for Dynacure include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Dynacure for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Dynacure with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Dynacure's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Dynacure with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Dynacure's' sector and industry vertical?

Access recent funding rounds and capital raises in Dynacure's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Dynacure